The Fly | ARTV

Off-the-Shelf Allogeneic Platform: Their proprietary platform enables large-scale production of non-gene-edited, cryopreserved, allogeneic natural killer (NK) cell therapies, offering significant advantages in accessibility and logistics over autologous or donor-specific approaches.

Scalable cGMP Manufacturing Expertise: Artiva possesses advanced capabilities for consistent, high-quality, and large-volume current Good Manufacturing Practice (cGMP) manufacturing of NK cell therapies, which is crucial for broad clinical development and eventual commercialization.

Robust Clinical and Preclinical Pipeline: A diversified pipeline targeting various hematologic and solid tumor indications, including innovative CAR-NK programs, provides multiple shots on goal and expands potential market reach across oncology.

Clinical Development Failure: Clinical trials for Artiva's NK cell therapies may fail to demonstrate sufficient efficacy or safety, halting development and preventing regulatory approval.

Regulatory Approval Uncertainty: Artiva's product candidates are subject to lengthy and uncertain regulatory approval processes by agencies like the FDA, and may never receive market authorization.

Significant Capital Needs: The company requires substantial additional funding to advance its pipeline through clinical trials and commercialization, which may not be available on acceptable terms or could lead to significant shareholder dilution.

Clinical Development Failure: Clinical trials for Artiva's NK cell therapies may fail to demonstrate sufficient efficacy or safety, halting development and preventing regulatory approval.

Regulatory Approval Uncertainty: Artiva's product candidates are subject to lengthy and uncertain regulatory approval processes by agencies like the FDA, and may never receive market authorization.